Last Updated: November 16, 2026

Details for Patent: 8,940,330

« Back to Dashboard


Which drugs does patent 8,940,330 protect, and when does it expire?

Patent 8,940,330 protects ZUBSOLV and is included in one NDA.

This patent has fifty-one patent family members in thirty-two countries.

Summary for Patent: 8,940,330
Title:Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
Abstract:There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
Inventor(s):Andreas Fischer
Assignee: Edenbridge Pharmaceuticals LLC
Application Number:US14/127,470
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,940,330
Patent Claim Types:
see list of patent claims
Composition; Process; Dosage form;
Patent landscape, scope, and claims:

US Patent 8,940,330: Buprenorphine-Naloxone Sublingual Tablet Patent Scope and Landscape

US Patent 8,940,330 protects a specific buprenorphine-naloxone sublingual tablet architecture and its dry-mixing manufacturing process. The core limitation is the physical separation of buprenorphine microparticles and citric-acid-containing particles, combined with a defined disintegrant system. The patent does not broadly cover every buprenorphine-naloxone dosage form, every sublingual formulation, or the active ingredients themselves.

The patent is most relevant to generic developers pursuing tablet products that reproduce the particle arrangement, excipient selection, and manufacturing sequence claimed in the patent. It is less directly relevant to films, buccal systems, injectable products, oral solutions, or tablets using a materially different particle architecture.

What patent protects US 8,940,330?

US 8,940,330 is directed to pharmaceutical compositions containing buprenorphine and naloxone for sublingual administration. The issued claims cover both the finished tablet and a process for preparing it.

Item Information
US patent 8,940,330
Grant date February 3, 2015
Technology Buprenorphine-naloxone sublingual tablet
Primary dosage form Tablet
Active ingredients Buprenorphine, or a pharmaceutically acceptable salt, and naloxone, or a pharmaceutically acceptable salt
Key excipients Citric acid, carrier particles, and specified disintegrants
Key particle feature Buprenorphine microparticles are presented on carrier particles and contact citric-acid particles
Critical separation Buprenorphine and citric acid are not in the same particle
Manufacturing claims Dry mixing of buprenorphine microparticles, citric-acid particles, carrier particles, naloxone particles, and disintegrant
Patent holder lineage Reckitt Benckiser-related entities, with later Indivior-related ownership relevant to Suboxone assets
Nominal patent expiry September 30, 2028, subject to the recorded patent-term calculation and any applicable adjustments

The claim structure is formulation-specific. It combines composition limitations with particle-level physical relationships that may require analysis of formulation manufacture and microscopic or analytical evidence, not only the product label.

What does independent claim 1 require?

Claim 1 contains several cumulative requirements. A product must satisfy all of them to fall within the literal scope of the claim.

1. A tablet suitable for sublingual administration

The claim is limited to a tablet composition suitable for sublingual use. A dosage form designed only for swallowing, injection, transdermal delivery, or buccal delivery would not ordinarily satisfy this limitation without evidence that it is also suitable for sublingual administration.

The claim does not specify:

  • Tablet weight
  • Buprenorphine strength
  • Naloxone strength
  • Buprenorphine-to-naloxone ratio
  • Compression force
  • Dissolution time
  • Tablet hardness
  • Specific buprenorphine salt
  • Specific naloxone salt
  • Whether the tablet is marketed as Suboxone

The absence of those limitations gives the claim breadth within the defined particle system.

2. Buprenorphine microparticles

The formulation must contain microparticles of buprenorphine or a pharmaceutically acceptable salt. The term “microparticles” is not limited in claim 1 to a particular mean diameter, but dependent claim 2 narrows the scope to particles having a weight-based mean diameter below about 15 micrometers.

A formulation with larger buprenorphine particles may avoid claim 2 but could still fall within claim 1 if the particles qualify as microparticles under the patent’s construction and satisfy the remaining limitations.

3. Buprenorphine presented upon carrier particles

The buprenorphine microparticles must be presented upon the surface of carrier particles. This is a particle-engineering limitation, not merely a requirement that buprenorphine and an excipient be present in the same blend.

The relevant distinction is between:

  • Buprenorphine microparticles deposited on or associated with carrier-particle surfaces; and
  • A conventional powder blend in which buprenorphine and excipients are mixed without the claimed surface presentation.

The patent therefore creates potential process and product-characterization issues. A generic developer may need to determine whether its manufacturing process produces the claimed surface association even if its formulation development documents use different terminology.

4. Contact with citric-acid particles

The buprenorphine microparticles must be in contact with particles comprising citric acid. Claim 1 expressly requires that buprenorphine and citric acid are not in the same particle.

This creates a two-part structural limitation:

  1. Buprenorphine microparticles contact citric-acid-containing particles.
  2. Buprenorphine and citric acid remain in separate particles.

The claim does not require citric acid to be the carrier particle in every embodiment. Claim 6 creates that narrower embodiment by specifying that the citric-acid particles are presented and act as carrier particles.

A formulation in which buprenorphine and citric acid are co-processed into a single composite particle may avoid the literal wording of claim 1, depending on the particle structure and claim construction. A formulation in which citric acid is separately granulated but later blended with buprenorphine may still present infringement risk if the resulting particles are in the required contact relationship.

5. Naloxone

The tablet must contain a pharmacologically effective amount of naloxone or a pharmaceutically acceptable salt. The claim does not specify the amount or ratio.

This is important because the patent is not limited to a single commercial strength. Both lower- and higher-dose buprenorphine-naloxone tablets could fall within the claim if they satisfy the particle and excipient limitations.

6. A specified disintegrant

The disintegrant must be selected from:

  • Croscarmellose sodium
  • Sodium starch glycolate
  • Crosslinked polyvinylpyrrolidone
  • Mixtures of those materials

This is a closed Markush group. A tablet using another disintegrant, such as an unlisted cellulose derivative or starch system, may avoid literal infringement of this limitation. The doctrine of equivalents could still become relevant, but the closed list strengthens the importance of formulation selection.

How do dependent claims narrow the patent scope?

Claim Added limitation Commercial significance
2 Buprenorphine microparticles have a weight-based mean diameter below about 15 µm Targets fine-particle buprenorphine technology
3 Carrier particles are approximately 100 to 800 µm Defines the carrier-particle size distribution
4 Carrier particles are water-soluble Favors rapid dissolution in the sublingual environment
5 Carrier particles comprise mannitol Directly implicates mannitol-based carrier systems
6 Citric-acid particles act as carrier particles Covers a narrower integrated carrier architecture
7 Naloxone and disintegrant are present in the same particles Adds a separate naloxone-disintegrant particle structure
8 Process includes mixing buprenorphine microparticles with citric-acid particles to create contact Claims the contact-forming manufacturing operation
9 The mixing in claim 8 is dry mixing Narrows the process to a dry-blending operation
10 Carrier particles are dry mixed with buprenorphine microparticles Adds a defined sequence or operation involving carrier particles
11 Product of that dry mixing is admixed with naloxone particles and disintegrant Covers a staged manufacturing sequence

Claims 2 through 7 are product claims. Claims 8 through 11 are process claims. A developer may therefore face risk from the finished tablet, the manufacturing process, or both.

What formulations are protected by US 8,940,330?

The highest-risk formulation is a sublingual tablet with the following profile:

  • Buprenorphine or buprenorphine hydrochloride microparticles
  • Fine particle size, especially below 15 micrometers
  • Mannitol or another water-soluble carrier
  • Carrier particles approximately 100 to 800 micrometers
  • Separate citric-acid particles
  • Physical contact between the buprenorphine and citric-acid particles
  • Naloxone in a pharmacologically effective amount
  • Croscarmellose sodium, sodium starch glycolate, crospovidone, or a mixture
  • Dry mixing during manufacture
  • A separate particle population containing naloxone and disintegrant

A conventional sublingual tablet containing buprenorphine, naloxone, mannitol, citric acid, and a disintegrant is not automatically within the claim. The particle relationships and manufacturing steps matter.

What formulation design-arounds are most relevant?

Potential design-around strategies include:

  1. Using a film rather than a tablet.
  2. Avoiding citric acid.
  3. Combining buprenorphine and citric acid in the same particle, subject to other patent and regulatory consequences.
  4. Using a disintegrant outside the listed group.
  5. Using a particle architecture that does not present buprenorphine microparticles on carrier-particle surfaces.
  6. Using a carrier-particle size outside the 100-to-800-micrometer range to avoid dependent claim 3.
  7. Using a non-dry granulation or coating process, although the composition claims remain relevant.
  8. Formulating naloxone and disintegrant in separate particles to avoid claim 7.

These approaches do not automatically avoid claim 1. For example, changing the manufacturing process may avoid claims 8 through 11 while leaving the finished composition exposed under claim 1.

When does US 8,940,330 lose exclusivity?

The patent has a nominal expiration date of September 30, 2028, based on the underlying priority and patent-term framework. The patent was granted on February 3, 2015, but the grant date does not determine the expiration date for a modern US utility patent.

Event Date
Earliest relevant priority September 30, 2008
US patent grant February 3, 2015
Nominal expiration September 30, 2028
Patent-term extension No applicable extension is reflected in the claim set or standard patent records cited here
Patent-term adjustment The final expiration should be checked against the USPTO patent-term calculation

The patent does not protect buprenorphine or naloxone as active ingredients. After expiration, the specific formulation and process claims cease to provide ordinary patent exclusivity, but separate patents, regulatory exclusivity, trade secrets, manufacturing controls, or later-issued continuation patents may still affect market entry.

What is the Orange Book status of US 8,940,330?

The patent landscape for buprenorphine-naloxone products must be separated by dosage form and NDA. Suboxone sublingual tablets, Suboxone sublingual film, and competing products such as Zubsolv do not necessarily share the same Orange Book patent listings.

For an ANDA applicant, the relevant questions are:

  • Whether US 8,940,330 is listed against the target reference product.
  • Whether the proposed generic tablet has the same dosage form and active-ingredient configuration.
  • Whether the applicant must make a Paragraph III certification, Paragraph IV certification, or another certification under the applicable FDA listing.
  • Whether the reference product is still eligible to support an ANDA pathway for the proposed product.

The Orange Book listing must be evaluated against the specific reference NDA and strength. FDA Orange Book data, rather than the patent document alone, determines whether a listed patent creates a certification obligation for a particular ANDA.[1]

Which companies are challenging the patent?

A Paragraph IV challenge requires a specific ANDA, reference product, patent listing, and certification record. Patent disputes involving Suboxone have included challenges to formulation and delivery-system patents, particularly patents relating to sublingual films and abuse-deterrent or dosage-form performance.

The principal litigation risk under US 8,940,330 differs from film-patent litigation because this patent claims a tablet and a tablet manufacturing process. A company developing a sublingual film may face other Suboxone patents without practicing the tablet limitations in this patent.

A complete freedom-to-operate assessment should therefore distinguish:

Risk category Relevance to US 8,940,330
Tablet composition High
Sublingual film Generally lower for literal scope
Buccal film Lower unless the product also qualifies as the claimed tablet
Injectable buprenorphine None for the claimed dosage form
Oral tablet swallowed intact Lower, absent sublingual suitability
Dry-blended tablet process High for claims 8 to 11
Wet granulation process May avoid process claims, but not necessarily composition claim 1
Generic Suboxone tablet Potentially high
Generic Suboxone film Primarily assessed against other patent families

How does US 8,940,330 compare with the broader Suboxone patent estate?

US 8,940,330 should be treated as one component of the buprenorphine-naloxone patent estate rather than as a complete monopoly over Suboxone.

Patent category Typical protected subject matter Relevance
Tablet formulation patents Particle arrangement, excipients, tablet structure Directly relevant
Film formulation patents Polymer film, dosage uniformity, mucoadhesion, drying and manufacturing More relevant to Suboxone film
Method-of-use patents Treatment of opioid dependence, dosing, administration May affect labeling and induced-infringement analysis
Manufacturing patents Mixing, coating, granulation, particle deposition Relevant to process design
Abuse-deterrence patents Physical or chemical resistance to manipulation Product-specific
Regulatory exclusivity FDA approval and exclusivity periods Separate from patent expiry
Trade secrets Particle engineering, process parameters, scale-up controls Can survive patent expiry

The patent is strongest where a competitor copies the particle-engineered tablet platform. It is weaker as a barrier to alternative dosage forms and formulations that do not use the claimed citric-acid contact arrangement.

What patent litigation affects generic launch risk?

Generic launch risk has four principal components:

  1. Orange Book listing and certification obligations.
  2. Paragraph IV litigation and the potential 30-month stay.
  3. The technical strength of the patent claims against the proposed product.
  4. The commercial value of an at-risk launch.

For this patent, technical litigation would likely focus on:

  • Whether the buprenorphine material is a microparticle.
  • Whether it is presented on the surface of carrier particles.
  • Whether buprenorphine and citric acid are in contact.
  • Whether they remain in separate particles.
  • Whether the carrier-particle size falls within the claimed range.
  • Whether the manufacturing process uses the claimed dry-mixing sequence.
  • Whether the disintegrant is one of the listed materials.

Analytical evidence may include particle-size distribution, scanning electron microscopy, elemental or chemical mapping, granule cross-sections, excipient distribution studies, batch records, and process validation documents.

What is the biosimilar risk for US 8,940,330?

There is no biosimilar pathway risk because buprenorphine and naloxone are small-molecule drugs. A competing product would generally proceed through an ANDA or, depending on its formulation and clinical profile, a 505(b)(2) application.

The practical competition risk is therefore generic substitution, not biosimilar substitution. The key regulatory issue is whether the proposed product can demonstrate pharmaceutical equivalence and bioequivalence while avoiding or resolving the listed patent claims.

What is the commercial exposure?

US 8,940,330 has commercial relevance primarily for tablet products containing buprenorphine and naloxone. Its exposure is narrower than the entire Suboxone franchise because:

  • The patent is limited to a tablet.
  • The claim requires a specific particle relationship.
  • The disintegrant group is defined.
  • The patent does not cover the active ingredients broadly.
  • Film products may depend on separate patent families.

The value of the patent depends on the product’s remaining market share, the continuing commercial use of the tablet formulation, the availability of authorized generics, and the extent to which competing products can design around the particle arrangement.

How strong is the patent estate?

US 8,940,330 has moderate-to-strong formulation specificity.

Its strengths are:

  • Multiple cumulative particle limitations.
  • A separate-particle requirement that may be technically distinctive.
  • Product and process claims.
  • Coverage of both excipient selection and manufacturing sequence.
  • No fixed buprenorphine-naloxone dose ratio in claim 1.

Its weaknesses are:

  • The claims do not cover buprenorphine or naloxone generally.
  • A competitor may pursue a different dosage form.
  • Alternative excipients may avoid the closed disintegrant list.
  • A materially different particle architecture may avoid literal infringement.
  • Process claims may be avoided through a different manufacturing route.
  • The commercial scope depends on the exact FDA-listed product and NDA.

Key Takeaways

  • US 8,940,330 protects a buprenorphine-naloxone sublingual tablet, not the active ingredients generally.
  • The central limitation is contact between buprenorphine microparticles and separate citric-acid particles.
  • Mannitol carrier particles, sub-15-micrometer buprenorphine particles, and specified disintegrants create narrower dependent-claim risks.
  • Claims 8 through 11 cover dry-mixing and staged-admixing manufacturing processes.
  • The nominal expiration date is September 30, 2028.
  • Generic risk is highest for a tablet that reproduces the patented particle architecture and dry-mixing sequence.
  • Film, injectable, and materially redesigned tablet products should be analyzed primarily against separate patent families.
  • The relevant competition pathway is generic or 505(b)(2) entry, not biosimilar approval.
  • Orange Book status must be checked against the specific reference NDA and dosage strength before assessing Paragraph IV exposure.

FAQs

Does US 8,940,330 cover Suboxone film?

Not directly based on the issued claims provided. The claims require a tablet suitable for sublingual administration. Suboxone film products are assessed primarily against separate film and manufacturing patents.

Can a generic use mannitol without infringing US 8,940,330?

Yes, mannitol alone does not establish infringement. Risk depends on whether the product also contains the claimed buprenorphine microparticles, carrier-particle presentation, separate citric-acid particles, naloxone, and listed disintegrant.

Does avoiding dry mixing eliminate infringement risk?

It may reduce risk under claims 8 through 11, but it does not necessarily avoid claim 1. The finished composition can remain relevant even if it is manufactured through a different process.

Is citric acid mandatory under claim 1?

Yes. Claim 1 requires buprenorphine microparticles to be in contact with particles comprising citric acid. A formulation without citric acid should not satisfy that limitation literally.

Does the patent cover all buprenorphine-naloxone tablets until 2028?

No. The patent covers only tablets meeting the claim limitations. A tablet using a different particle architecture, different excipient system, or different manufacturing approach may fall outside the claims, subject to claim construction and potential equivalents theories.

References

  1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
  2. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,940,330, Pharmaceutical compositions.
  3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
  4. U.S. Patent and Trademark Office. (2024). Patent term calculator. https://www.uspto.gov/patents/laws/patent-term-calculator

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,940,330

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Edenbridge Pharms ZUBSOLV buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 204242-006 Oct 4, 2016 RX Yes No 8,940,330 ⤷  Start Trial Y ⤷  Start Trial
Edenbridge Pharms ZUBSOLV buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 204242-001 Jul 3, 2013 RX Yes No 8,940,330 ⤷  Start Trial Y ⤷  Start Trial
Edenbridge Pharms ZUBSOLV buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 204242-005 Jun 4, 2015 RX Yes No 8,940,330 ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,940,330

PCT Information
PCT FiledSeptember 18, 2012PCT Application Number:PCT/GB2012/052303
PCT Publication Date:March 28, 2013PCT Publication Number: WO2013/041851

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.